After three decades of the War on Cancer, progress in developing therapies has been disappointing. But the relative success of Gleevec in the treatment of chronic myelogenous leukaemia marks something of a milestone. In the 10 months since its introduction in the United States, it has shown that molecularly targeted drugs have a promising future.
A News Feature in this issue of Nature (Vol. 416, No. 6880, 04 Apr 02) reviews progress in converting our knowledge of molecular biology and genomics into advanced diagnostic and therapeutic tools.
(C) Nature press release.
Message posted by: Trevor M. D'Souza